Pediatric Sarcoma Partnerships Position Salarius as a strategic partner for large oncology companies pursuing pediatric and sarcoma programs, leveraging seclidemstat’s regulatory designations to accelerate development and enable licensing in Ewing related sarcomas and similar biology cancers, with credibility boosted by the MD Anderson collaboration and foundation funding.

Licensing Seclidemstat Target licensing or co development opportunities for seclidemstat across Ewing related sarcomas and other FET rearranged tumors, emphasizing regulatory incentives and non dilutive funding from CPRIT and pediatric foundations to de risk deals and attract partner investment.

SP-3164 Partnerships Explore collaborations to advance SP-3164 in hematologic and solid tumors, leveraging the DeuteRx portfolio and Salarius' targeted protein degrader platform to speed discovery and broaden commercialization opportunities with industry or academic partners.

Non-dilutive Support Highlight prior non-dilutive funding and award history from CPRIT and the National Pediatric Cancer Foundation to demonstrate program viability and funding readiness when engaging potential collaborators and investors.

Focused Strategy Leverage Salarius’ clinical stage focus and compact team to pursue niche, partner driven programs with academic centers and specialty oncology companies, using existing relationships to accelerate deal flow and trials in orphan indications.